From Send2Press® Newswire — Print Friendly Version
Drugs and Pharmaceuticals News
P R E S S R E L E A S E :
Epeius Biotechnologies Reports Major Clinical Advances:
Noteworthy Clinical Case Studies in Cancer Gene Therapy
Tue, 04 May 2010, 12:06:12 EDT
SAN MARINO, Calif. (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies
Corporation, a leader in the field of targeted genetic medicine, reports the publication of
three major publications in the field. The first article entitled "Rexin-G, A Targeted
Genetic Medicine for Metastatic Cancer" (Expert Opinion on Biological Therapy, May,
2010) documents the development of Rexin-G: a tumor-targeted retrovector bearing a
cytocidal cyclin G1 construct; the first targeted gene therapy vector to gain FDA Fast
Track designation and Orphan Drug priorities for multiple cancer indications in the USA.
What the reader will gain: In recording the development of Rexin-G as a novel targeted
biological therapy, this review also highlights important aspects of vector engineering
which served to overcome the physiological barriers to gene delivery as it addresses the
key regulatory issues involved in the development of a targeted gene therapy product.
Take home message: Progressive clinical development of Rexin-G demonstrates the
potential safety and efficacy of targeted genetic medicine in otherwise intractable cancers, while validating the design
engineering of the molecular biotechnology platform.
The second article, entitled "Noteworthy Clinical Case Studies in Cancer Gene Therapy" (Intl. J. Oncology, April, 2010)
highlights important aspects of Rexin-G bio-pharmacology, as this tumor-targeted vector advances as an efficacious anti-
cancer agent. What the reader will gain: These remarkable case studies, in and of themselves, reveal important aspects of the
molecular pharmacology, advanced clinical protocols, refinement of patient monitoring, expanding treatment options, and
strategic medical approaches to patient care that exemplify and thereby ex